Loading...
•
Sep 30, 2022
DexCom Q3 2022 Earnings Report
Dexcom's revenue grew, G7 was launched in five countries and access to real-time CGM was expanded.
Key Takeaways
Dexcom's third-quarter revenue grew by 18% year-over-year to $769.6 million. The company launched G7 in five countries and expanded access to real-time CGM.
Revenue grew 18% versus the same quarter of the prior year to $769.6 million.
U.S. revenue growth of 17% and international revenue growth of 22%.
GAAP operating income of $147.5 million or 19.2% of revenue.
Initiated the international roll-out of Dexcom G7 with launches in the United Kingdom, Ireland, Germany, Austria, and Hong Kong.
Revenue by Geographic Location
Forward Guidance
The company is updating fiscal 2022 revenue and Non-GAAP Gross Profit Margin guidance, and reiterating guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels:
Positive Outlook
- Revenue of approximately $2.88 - 2.91 billion (18-19% reported growth)
- Non-GAAP Gross Profit Margin of approximately 64%
- Non-GAAP Operating Margin of approximately 16%
- Adjusted EBITDA Margin of approximately 25%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...